Lucid Diagnostics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lucid Diagnostics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.35M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $2.43M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $377.0K | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | $500.0K | Apr 6, 2022 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $4.35M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $2.43M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $377.0K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $500.0K | Mar 14, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $377.0K | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $500.0K | Mar 14, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.01M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($45.53M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($52.67M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($56.17M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($28.08M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($8.28M) | Apr 6, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.64M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($46.05M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($48.48M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($56.25M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($27.42M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($8.28M) | Apr 6, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.68M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.99M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $7.25M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $11.26M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $9.30M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $5.44M | Apr 6, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $21.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $7.0K | Apr 6, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($46.49M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($44.14M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($32.82M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($29.69M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($17.67M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($5.63M) | Apr 6, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.0K | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $296.0K | Mar 25, 2026 |
| FY2023 | Dec 31, 2022 | $3.20M | Mar 25, 2024 |
| FY2021 | Dec 31, 2021 | $862.0K | Apr 6, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.45M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $30.72M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $27.27M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $32.51M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $59.00M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $2.20M | Apr 6, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.51M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $25.32M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | $29.58M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $9.46M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $4.26M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $15.71M | Apr 6, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.94M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.39M | Mar 25, 2026 |
| FY2025 | Dec 31, 2023 | ($2.31M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2022 | $23.05M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $54.74M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | ($13.52M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($5.31M) | Apr 6, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($274.34M) | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | ($203.77M) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | ($150.74M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($98.08M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($41.90M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($13.83M) | Apr 6, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $22.36M | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | $18.90M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $22.47M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $53.66M | Mar 14, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 24, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 25, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 131.10M | Mar 25, 2026 |
| FY2025 | Dec 31, 2024 | 63.07M | Mar 25, 2026 |
| FY2024 | Dec 31, 2023 | 42.33M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 40.52M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 34.92M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 14.11M | Apr 6, 2022 |